Hans Gelderblom
汉斯·盖尔德布洛姆
MD, PhD
Professor and Head of Medical Oncology医学肿瘤科教授兼主任
👥Biography 个人简介
Professor Hans Gelderblom is a leading European expert in sarcoma and gastrointestinal stromal tumors at Leiden University Medical Center. He has led pivotal trials for imatinib, sunitinib, and regorafenib in GIST, and is a key contributor to EORTC sarcoma trial design.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
GIST Treatment Optimization
Led EORTC trials establishing optimal imatinib dosing and duration for advanced GIST, and contributed to regorafenib third-line evidence, refining treatment sequencing for this rare tumor.
Sarcoma Clinical Trials
Co-chair of EORTC Soft Tissue and Bone Sarcoma Group trials, generating evidence base for trabectedin, pazopanib, and other agents in rare sarcoma subtypes.
Neuroendocrine Tumor Management
Advanced clinical understanding of systemic therapy for neuroendocrine tumors, contributing to ENETS guidelines and somatostatin analogue therapeutic strategies.
Representative Works 代表性著作
Regorafenib for patients with gastrointestinal stromal tumor who progressed following imatinib and sunitinib
Lancet (2013)
GRID trial demonstrating regorafenib benefit in third-line GIST, establishing the third approved therapy for this disease.
Pazopanib for metastatic soft-tissue sarcoma
Lancet (2012)
PALETTE trial establishing pazopanib as the first approved VEGFR inhibitor for non-adipocytic soft tissue sarcoma after chemotherapy failure.
Imatinib dose and survival in gastrointestinal stromal tumors
European Journal of Cancer (2010)
Meta-analysis correlating imatinib dose with survival outcomes in GIST, informing dose-selection guidelines across KIT mutation subtypes.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 汉斯·盖尔德布洛姆 的研究动态
Follow Hans Gelderblom's research updates
留下邮箱，当我们发布与 Hans Gelderblom（Leiden University Medical Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment